Synthorx, Inc. announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from September 27 through October 1, 2019. The preclinical studies to be presented at ESMO 2019 reinforce THOR-707’s ability to induce CD8+ T cell tumor infiltration and anti-tumor efficacy in a dose-dependent manner. Further, these preclinical data highlight the additive efficacy when a PD-1 checkpoint inhibitor is combined with THOR-707, resulting in the promotion of long-term survival and the rejection of tumor cells on re-challenge in two animal models. Preclinical molecular profiling data will also be presented, demonstrating THOR-707’s induction of critical immunological mechanisms to elicit tumor infiltration and destruction, including expression markers of response. Synthorx is conducting HAMMER, a global Phase 1/2, first-in-human clinical trial of THOR-707 in adult subjects with advanced or metastatic solid tumors. The single agent and combination arms of the trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of THOR-707 as a single agent and together with a checkpoint inhibitor.